Source: Web Search Publisher: M/s. ASPIRO PHARMA LIMITED
Pantoprazole sodium is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE).
Safety and efficacy of Pantoprazole sodium as a treatment of patients with GERD and a history of EE for more than 10 days have not been demonstrated.
Pantoprazole sodium is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.
The recommended adult dosage of Pantoprazole sodium is 40 mg given once daily by intravenous infusion for 7 to 10 days.
Discontinue treatment with PROTONIX I.V. as soon as the patient is able to receive treatment with PROTONIX Delayed-Release Tablets or Oral Suspension.
Data on the safe and effective dosing for conditions other than those described such as lifethreatening upper gastrointestinal bleeds, are not available. Pantoprazole sodiumonce daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions.
Only for intravenous infusion; other parenteral routes of administration are not recommended.
The reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light.
Do not freeze the reconstituted solution.
The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light.
Do not freeze the reconstituted solution.
The recommended adult dosage of Pantoprazole sodium is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient needs based on acid output measurements. In those patients who need a higher dosage, 80 mg intravenously every 8 hours is expected to maintain acid output below 10 mEq/h. Daily doses higher than 240 mg or administered for more than 6 days have not been studied. Transition from oral to intravenous and from intravenous to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of effect of suppression of acid secretion. Patients with ZE Syndrome may be vulnerable to serious clinical complications of increased acid production even after a short period of loss of effective inhibition.
Only for intravenous infusion; other parenteral routes of administration are not recommended.
The reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light.
Do not freeze the reconstituted solution.
The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light.
Do not freeze the reconstituted solution.
Experience in patients taking very high doses of pantoprazole (greater than 240 mg) is limited. Adverse reactions seen in spontaneous reports of overdose generally reflect the known safety profile of pantoprazole.
Pantoprazole is not removed by hemodialysis. In case of overdose, treatment should be symptomatic and supportive.
Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of acute toxicity were hypoactivity, ataxia, hunched sitting, limbsplay, lateral position, segregation, absence of ear reflex, and tremor.
24 Months.
Store below 30°C, Protect from light.
1×1's Pack: 10 mL Clear Tubular Glass Vial.
Not Applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.